Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Tesetaxel"'
Autor:
Agostina Stradella, Joanne L. Blum, Sung-Bae Kim, Lee S. Schwartzberg, Sara M. Tolaney, Thomas Wei, Hope S. Rugo, Stew Kroll, Yin-Hsun Feng, Igor Bondarenko, Yann Izarzugaza, Mafalda Oliveira, Noshir Anthony Dacosta, Arlene Chan, Michel Pavic, Mei-Ching Liu, Maria Eva Peréz Lopéz, Elizabeth A. Mittendorf, Samuel Guan Wei Ow, Joe O'Connell
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Yann Izarzugaza, Gavin Marx, Igor Bondarenko, Andrew D. Seidman, Mafalda Oliveira, Lee S. Schwartzberg, Joe O'Connell, Yin-Hsun Feng, Sung-Bae Kim, Y.S. Chae, Hope S. Rugo, Julie Lemieux, Joyce O'Shaughnessy, Thomas Wei, Jamil Asselah, Noshir Anthony Dacosta, Mei-Ching Liu, Gail S. Wright
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Yaroslav Shparyk, Andrew D. Seidman, Yee Soo Chae, Lee S. Schwartzberg, Thomas Wei, Yevhen Hotko, Yen-Shen Lu, Sina Vatandoust, Sara M. Tolaney, Noshir Anthony Dacosta, Sabela Recalde, Chi-Feng Chung, Igor Bondarenko, Hope S. Rugo, Nuria Chic, Patricia Gomez, Joyce O'Shaughnessy, Joe O'Connell, Lawrence Panasci, Gail Lynn Shaw Wright
Publikováno v:
Journal of Clinical Oncology. 39:1061-1061
1061 Research Funding: Odonate Therapeutics, Inc. Background: T is a novel, oral taxane with unique properties, including: oral administration with a low pill burden, a long (8-day) half-life in humans, once-every-3-weeks dosing, no observed hypersen
Autor:
Igor Bondarenko, Gun Min Kim, Lee S. Schwartzberg, Sara M. Tolaney, Thomas Wei, Agostina Stradella, Mei-Ching Liu, Yen-Shen Lu, Joe O'Connell, Vance Wright-Browne, Samuel Guan Wei Ow, Tira Jing Ying Tan, Hope S. Rugo, Noshir Anthony Dacosta, Yann Izarzugaza, Arlene Chan, Elizabeth A. Mittendorf, Maria Eva Perez, Mafalda Oliveira, Michel Pavic
Publikováno v:
Journal of Clinical Oncology. 38:TPS1111-TPS1111
TPS1111 Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. T is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Igor Bondarenko, Thomas Wei, Nadia Harbeck, Jeff Vacirca, Seock-Ah Im, Michael Untch, Denise A. Yardley, Stew Kroll, Andrew D. Seidman, Kevin Tang, Hope S. Rugo, Joe O'Connell, Lee S. Schwartzberg, Joyce O'Shaughnessy, Martine Piccart, Véronique Diéras, Javier Cortes, Stephen Chan, Mark D. Pegram
Publikováno v:
Journal of Clinical Oncology. 37:TPS1107-TPS1107
TPS1107 Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel (T) is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low
Autor:
Nadia Harbeck, Denise A. Yardley, Seock-Ah Im, Stew Kroll, Kevin Tang, Igor Bondarenko, Luca Gianni, Lee S. Schwartzberg, Michael Untch, Javier Cortes, Véronique Diéras, Joe O'Connell, Martine Piccart-Gebhart, Hope S. Rugo, Thomas Wei, Andrew D. Seidman, Joyce O'Shaughnessy, Stephen Chan, Mark D. Pegram, Jeffrey L. Vacirca
Publikováno v:
Journal of Clinical Oncology. 36:TPS1106-TPS1106
TPS1106Background: Chemotherapy treatments that offer improved quality of life are needed. Tesetaxel (T) is a novel, oral taxane that has potential advantages over currently available taxanes, incl...
Autor:
Lee S. Schwartzberg, Andrew D. Seidman, Joe O'Connell, Vinay K. Gudena, Kevin Tang, Joyce O'Shaughnessy, Stew Kroll, Peter Rubin
Publikováno v:
Journal of Clinical Oncology. 36:1042-1042
1042Background: Chemotherapy treatments that offer improved quality of life are needed. Tesetaxel (T) is a novel, oral taxane that has potential advantages over currently available taxanes, includi...
Autor:
John Paul Flores, M. Wasif Saif
Publikováno v:
Clinical investigation. 3(4)
The oral taxanes are analogues of existing taxanes with a possible broad range of antitumor activity. They also have the potential advantages of ease of administration, better efficacy and lesser toxicity than currently available taxanes. These drugs
Autor:
Kyri Papadopoulos, Drew W. Rasco, Amita Patnaik, T. Cousin, L. Itri, Muralidhar Beeram, Anthony W. Tolcher
Publikováno v:
Annals of Oncology. 23:ix165-ix166
Autor:
Kaoru Tanaka, Hidetoshi Hayashi, Hisato Kawakami, Taroh Satoh, Yasuhito Fujisaka, T. Kudoh, Takayasu Kurata, Kazuhiko Nakagawa, T. Cousin, Wataru Okamoto
Publikováno v:
Annals of Oncology. 23:ix167
Background Tesetaxel is an orally administered taxane that, unlike IV analogs, is not a Pgp substrate (a primary mechanism of taxane resistance). This novel agent has a long plasma T½ (∼180 h), allowing administration once every 3 weeks (Q3W). Tes